This histogram enumerates side effects from a completed 2021 Phase 3 trial (NCT04355767) in the Convalescent Plasma ARM group. Side effects include: Pneumonia with 12%, Infusion related reaction with 4%, Hypoxia with 2%, Dyspnea with 2%, Acute respiratory failure with 1%.
1 Treatment Group
1 of 1
52 Total Participants · 1 Treatment Group
Primary Treatment: Convalescent Plasma · No Placebo Group · Phase 2
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.